X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ACT017 (glenzocimab), a humanized mAb fragment directed against a novel target, platelet glycoprotein VI. Glenzocimab inhibits platelet binding to the thrombus without affecting physiological hemostasis, thereby limiting the bleeding risk, particularly in the brain stroke.
Lead Product(s): Glenzocimab
Therapeutic Area: Neurology Product Name: ACT017
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2023
Details:
ACT017 (glenzocimab), a humanized mAb fragment directed against a novel target, platelet glycoprotein VI. Glenzocimab inhibits platelet binding to the thrombus without affecting physiological hemostasis, thereby limiting the bleeding risk, particularly in the heart attacks.
Lead Product(s): Glenzocimab
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ACT017
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: The University of Birmingham
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
Details:
ACT017 (glenzocimab), a humanized mAb fragment directed against a novel target, platelet glycoprotein VI. Glenzocimab inhibits platelet binding to the thrombus without affecting physiological hemostasis, thereby limiting the bleeding risk, particularly in the brain stroke.
Lead Product(s): Glenzocimab
Therapeutic Area: Neurology Product Name: ACT017
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2023
Details:
ACT017 (glenzocimab), a humanized mAb fragment directed against a novel target, platelet glycoprotein VI. Glenzocimab inhibits platelet binding to the thrombus without affecting physiological hemostasis, thereby limiting the bleeding risk, particularly in the brain.
Lead Product(s): Glenzocimab
Therapeutic Area: Neurology Product Name: ACT017
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
ACT017 (glenzocimab), a humanized mAb fragment directed against a novel target of major interest, platelet GPVI. Glenzocimab inhibits platelet binding to the thrombus without affecting physiological hemostasis, thereby limiting the bleeding risk, particularly in the brain.
Lead Product(s): Glenzocimab
Therapeutic Area: Neurology Product Name: ACT017
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2022
Details:
Acticor Biotech is developing glenzocimab (ACT017), a humanized monoclonal antibody (mAb) fragment directed against a novel target of major interest, platelet glycoprotein VI (GPVI). Glenzocimab inhibits platelet binding to the thrombus.
Lead Product(s): Glenzocimab
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ACT017
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: University of Birmingham
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 22, 2022
Details:
ACT017 (glenzocimab), humanized mAB fragment directed against a novel target of major interest, platelet glycoprotein VI, inhibits platelet binding to thrombus without affecting physiological hemostasis, thereby limiting the bleeding risk, particularly in brain.
Lead Product(s): Glenzocimab
Therapeutic Area: Neurology Product Name: ACT017
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2022
Details:
This Dose Escalation Phase of Glenzocimab as Add-on to Thrombolysis and/or Mechanical Thrombectomy was successfully completed with 60 patients enrolled from 6 European countries (France, Belgium, Germany, Spain, Switzerland and Italy).
Lead Product(s): Glenzocimab
Therapeutic Area: Neurology Product Name: ACT017
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
